Who are néfopam's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nefopam administration and prelevment, Tesomet "Low dose" in fasted condition, Tesomet "High dose" in fed condition, Centanafadine SR, Nefopam ampule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/n-fopam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

néfopam — Competitive Intelligence Brief

néfopam (néfopam) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-opioid analgesic; monoamine reuptake inhibitor. Area: Pain Management.

marketed Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter (NET); dopamine transporter (DAT); serotonin transporter (SERT) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

néfopam (néfopam) — University Hospital, Bordeaux. Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
néfopam TARGET	néfopam	University Hospital, Bordeaux	marketed	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter (NET); dopamine transporter (DAT); serotonin transporter (SERT)
Nefopam administration and prelevment	Nefopam administration and prelevment	University Hospital, Rouen	marketed	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter, dopamine transporter, serotonin transporter
Tesomet "Low dose" in fasted condition	Tesomet "Low dose" in fasted condition	Saniona	marketed	Monoamine reuptake inhibitor + biguanide combination	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase
Tesomet "High dose" in fed condition	Tesomet "High dose" in fed condition	Saniona	marketed	Monoamine reuptake inhibitor + biguanide combination	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase
Centanafadine SR	Centanafadine SR	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Triple monoamine reuptake inhibitor	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)
Nefopam ampule	Nefopam ampule	Ministry Of Health / Nineveh Health Directorate	phase 3	Non-opioid analgesic; monoamine reuptake inhibitor	Norepinephrine transporter, dopamine transporter, serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-opioid analgesic; monoamine reuptake inhibitor class)

Ministry Of Health / Nineveh Health Directorate · 1 drug in this class
University Hospital, Bordeaux · 1 drug in this class
University Hospital, Rouen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). néfopam — Competitive Intelligence Brief. https://druglandscape.com/ci/n-fopam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab